pourdeac
Well-known member
- Joined
- Mar 31, 2011
- Messages
- 2,405
- Reaction score
- 136
What part wows you. The part where people seem to have bizarre faith in "experts" who really aren't (especially compared to industry)? I've sat on many drug discovery NIH study section panels. I see what goes on and why. It's not exactly pretty. 50% of the people on those panels don't know what they're talking about and they evaluate everything based on an extremely narrow expertise that does not apply to the real world.2nd bit I agree with, 1st part, wow.
Twice I've seen projects that will no doubt what-so-ever fail, and get 2s across the board because these academic "experts" don't understand or appreciate how impossible the project would be to do from my area of expertise...medicinal chemistry. The pharmacologists and clinicians just liked the way it sounded. Major waste of 10m.
That kind of decision making does not go on in the commercial side. In fact when a commercial expert is on one of these study sections, the academics most often defer expertise to the commercial expert (afraid of being shown up by someone with nothing to lose because the commmercial expert does not have to get THEIR grant reviewed). It's funny watching a commercial drug discovery guy skewer some clueless pompous academician.
So claims like in that article are incredibly ignorant. They don't understand the perils of intellectual tribalism that exists when you remove a commercial pressure that prevents such tunnel vision from occurring. That costs WAY more than any threat of efficiency loss from marketing...the great health corporate evil that academic economists lock onto.